| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000017786 |
| Receipt No. | R000020540 |
| Scientific Title | Prostective evaluation study for establishing treatment of pediatric fuctional gstrointestinal disorder and orthostatic disregulation patients |
| Date of disclosure of the study information | 2015/07/01 |
| Last modified on | 2020/06/07 (Ver. 10) |
| Basic information | ||
| Public title | Prostective evaluation study for establishing treatment of pediatric fuctional gstrointestinal disorder and orthostatic disregulation patients | |
| Acronym | Study for establishing treatment in pediatric fuctional gastrointestinal disorder patients | |
| Scientific Title | Prostective evaluation study for establishing treatment of pediatric fuctional gstrointestinal disorder and orthostatic disregulation patients | |
| Scientific Title:Acronym | Study for establishing treatment in pediatric fuctional gastrointestinal disorder patients | |
| Region |
|
|
| Condition | ||
| Condition | pediatric functional gastrointestinal disorders
Orthostatic dysregulation |
|
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To elucidate the pathogenesis of pediatric gastrointestinal disorders |
| Basic objectives2 | Others |
| Basic objectives -Others | To establish the examinations and treatments in pediatric functional gastrointestinal disorders |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | To evaluate emptying and peristalsis of stomach
To evaluate small intestinal bacterial overgrowth |
| Key secondary outcomes | autonomic nervous function, cognitive assessment, psycological assessment, Quality of life assessment, stress assessment |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |||
| No. of arms | 1 | ||
| Purpose of intervention | Diagnosis | ||
| Type of intervention |
|
||
| Interventions/Control_1 | 1.Hydrogen Breath Tests
At the start of the test, fasting breath hydrogen is estimated 3 to 4 times. Subsequently, the subject ingests a fixed amount of gulucose(1g/kg, max100g). 2.13C-acetate Breath Test At the start of the test, fasting breath is measured. Subsequently, the subject ingests a fixed amount of 13C-acetate 100mg and Racol 200ml. 3.Electrogastrography Electrogastrography recordings was obtained for 30 min in the fasting state and for another 30 min after a test meal, Racol 200ml. |
||
| Interventions/Control_2 | |||
| Interventions/Control_3 | |||
| Interventions/Control_4 | |||
| Interventions/Control_5 | |||
| Interventions/Control_6 | |||
| Interventions/Control_7 | |||
| Interventions/Control_8 | |||
| Interventions/Control_9 | |||
| Interventions/Control_10 | |||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | <Functional gastrointestinal disorders>
Must include all of the following. 1.At obtaining informed consent, => 6 y.o and < 20 y.o 2.Based on ROMA 3 criteria, diagnosed as fuctional gastrointestinal disorders 3.It is possible to cease treatment affecting gastrointestinal function, autonomic nerve system and psycosocial factors 4.No evidence of respiratory disease and liver disease 5.No history of gastrointestinal surgery 6.Not suffering from acute disorders such as upper respiratory inflammatory and acute gastroenteritis 7.After receiving a sufficient explanation, obtained from patients or legal representative informed consent <Orthostatic dysregulation patients> Must include all of the following. 1.At obtaining informed consent, => 6 y.o and < 20 y.o 2.Must fulfill criteria by standing test 3.No evidence of structural disease 4.It is possible to cease treatment 5.Not suffering from acute disorders such as upper respiratory inflammatory and acute gastroenteritis 6.After receiving a sufficient explanation, obtained from patients or legal representative informed consent |
|||
| Key exclusion criteria | Include one or more of the following.
1.At informed consent, < 6 y.o and => 20y.o 2.It is impossible to cease treatment 3.History of gastrointestinal surgery 4.It is impossible to communicate 5.Determined to inappreciate by investigator |
|||
| Target sample size | 40 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Juntendo University | ||||||
| Division name | Pediatrics and Adolescent Medicine | ||||||
| Zip code | 113-8421 | ||||||
| Address | Hongo 2-1-1, Bunkyo, Tokyo | ||||||
| TEL | 03-3813-3111 | ||||||
| tshimizu@juntendo.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Juntendo University | ||||||
| Division name | Pediatrics and Adolescent Medicine | ||||||
| Zip code | 113-8421 | ||||||
| Address | Hongo 2-1-1, Bunkyo, Tokyo | ||||||
| TEL | 03-3813-3111 | ||||||
| Homepage URL | |||||||
| khosoi@juntendo.ac.jp | |||||||
| Sponsor | |
| Institute | Juntendo University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Juntendo University research funding |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | The ethics committee of Juntendo Univercity |
| Address | Hongo 2-1-1, Bunkyo, Tokyo |
| Tel | 03-5802-1584 |
| hmasuko@juntendo.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 20 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000020540 |